Stockreport
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
US:NASDAQ Investor Relations: businesswire.com/news/home/20170630005160/en/precipio-diagnostics-transgenomic-complete-merger
PDF
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the presentation of preclinical data for MRT5005, a first-in-class mRNA therapeutic designed to treat all patients with cystic fibrosis regardless of mutation. The presentation includes data demonstrating that MRT5005 was efficiently delivered to the lungs of rodents and non-human primates by nebulization, resulting in functional cystic fibrosis transmembrane conductance regulator (CFTR) protein expression. These data will be featured in a poster presentation at the 32nd Annual North American Cystic Fibrosis Conference (NACFC) taking place in Denver, Colorado, from October 18-20, 2018. “MRT5005
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | TBIO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
TBIO alerts
TBIO alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBIO alerts
High impacting Translate Bio, Inc news events
Weekly update
A roundup of the hottest topics
TBIO
NEWS
NEWS
- Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)[GlobeNewswire]
- Moderna Proposes Terms For $500 Million Biotech IPO [Seeking Alpha][Seeking Alpha]
- Translate Bio up 22% [Seeking Alpha][Seeking Alpha]
- Translate Bio Inc (NASDAQ: TBIO) had its price target raised by analysts at Leerink Swann from $24.00 to $25.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Moderna Seeks $500 Million In IPO [Seeking Alpha][Seeking Alpha]
- More
TBIO
SEC Filings
SEC Filings
- 11/8/18 - Form 10-Q
- 10/17/18 - Form SC
- TBIO's page on the SEC website
- More